Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin collaborates with LABORATORIOS ERN to launch Luforbec® (beclometasone/formoterol) pMDI in Spain. This expands its global respiratory care portfolio and market presence, leveraging ERN's local expertise and Lupin's manufacturing excellence.
Jun 08 2026 12:19:58
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Limited announced US FDA approval for its ranibizumab, Ranluspec™ Injection, as an interchangeable biosimilar referencing Lucentis®. This approval is significant as Ranluspec™ is the only interchangeable biosimilar approved in both vials and pre-filled syringes, strengthening Lupin's biosimilar portfolio and market access.
Jun 04 2026 23:06:29
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin and its partner Natco Pharma received US FDA approval for Eribulin Mesylate Injection, a generic version of a drug with estimated annual sales of $43.7 million. This approval allows the companies to launch a new product for metastatic breast cancer treatment in the US market.
Jun 03 2026 11:02:54
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin obtained US FDA approval for its Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets. This approval grants Lupin first-to-file status and 180-day generic drug exclusivity in the U.S. market, targeting a product with estimated annual sales of $132.8 million.
May 29 2026 19:03:27
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Lupin's wholly-owned subsidiary, Nanomi B.V., has updated that the acquisition of minority shareholding in Multicare Pharmaceuticals Philippines, Inc. is now expected to close by July 2026, a slight delay from the previously intimated May 2026 timeline. The transaction remains in progress subject to closing conditions.
May 29 2026 15:59:24
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin's Ankleshwar facility has received the Establishment Inspection Report (EIR) from the U.S. FDA. This positive outcome follows a product-specific Pre-Approval Inspection conducted from March 2 to March 7, 2026, confirming regulatory compliance.
May 28 2026 09:51:22
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Lupin will participate in three analyst/institutional investor group meetings from June 2 to June 4, 2026. These events include conferences hosted by BofA Securities, Morgan Stanley, and Citi.
May 25 2026 17:30:45
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin received China's NMPA approval for Oseltamivir Phosphate Oral Suspension, marking its debut in the Chinese market. This expands Lupin's global footprint for high-quality, affordable medicines, especially for pediatric use, in partnership with Yabao Pharmaceuticals.
May 22 2026 15:54:05
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Limited has been featured for the first time in the Dow Jones Best-in-Class Indices (DJBIC) for 2026, covering both World and Emerging Markets indices. This inclusion highlights the company's strong commitment to sustainable and ethical business practices, reinforcing its credibility with global investors.
May 19 2026 11:45:52
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin secured tentative approval from the U.S. FDA for Revefenacin Inhalation Solution, 175 mcg/3 mL Unit-Dose Vials. This generic drug is indicated for Chronic Obstructive Pulmonary Disease (COPD), targeting a market with $260.7 million in annual sales.
May 18 2026 21:11:56
Read More